A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma
Public ClinicalTrials.gov record NCT03181126. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 Dose Escalation, Open-Label Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This dose-escalating study is to determine the safety, pharmacokinetics, and preliminary efficacy of venetoclax in combination with navitoclax and chemotherapy in adult and pediatric participants with relapsed/refractory acute lymphoblastic leukemia (ALL) or relapsed/refractory lymphoblastic lymphoma. A safety expansion cohort of approximately 20 patients may be enrolled in addition to the 50 participants in dose-escalation cohort.
Study identification
- NCT ID
- NCT03181126
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 69 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 4 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 27, 2017 (Actual)
- Primary completion
- Nov 11, 2020 (Actual)
- Completion
- Nov 14, 2020 (Actual)
- Last update posted
- Oct 14, 2021
2017 – 2020
United States locations
- U.S. sites
- 12
- U.S. states
- 9
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope /ID# 169029 | Duarte | California | 91010 | — |
| LPCH Stanford /ID# 163337 | Palo Alto | California | 94304 | — |
| University of Chicago /ID# 163369 | Chicago | Illinois | 60637 | — |
| Washington University-School of Medicine /ID# 165689 | St Louis | Missouri | 63110 | — |
| Univ NC Chapel Hill /ID# 163509 | Chapel Hill | North Carolina | 27514-4220 | — |
| Cincinnati Children's Hospital /ID# 164619 | Cincinnati | Ohio | 45229 | — |
| Nationwide Childrens Hospital /ID# 163372 | Columbus | Ohio | 43205 | — |
| Oregon Health and Science University /ID# 165690 | Portland | Oregon | 97239 | — |
| St Jude Children's Research Hospital /ID# 163335 | Memphis | Tennessee | 38105 | — |
| UT Southwestern Medical Center /ID# 163346 | Dallas | Texas | 75390-7208 | — |
| MD Anderson Cancer Center at Texas Medical Center /ID# 163327 | Houston | Texas | 77030-4000 | — |
| University of Wisconsin-Madiso /ID# 165691 | Madison | Wisconsin | 53705 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03181126, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 14, 2021 · Synced Oct 31, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03181126 live on ClinicalTrials.gov.